Tulane Department of Urology is the first and most experienced in the Gulf South in robotic procedures for prostate cancer and kidney cancer. Tulane Urology has as long history of being the regional and national leaders in providing minimally invasive surgical procedures for various urologic maladies.
From Nephroscopy to Ureteroscopy to Laparoscopy to Laser Surgery, Tulane Urology has been in most instances the first and the most experienced in such minimally invasive procedures in the entire Gulf South.
This same spirit of innovation and experience brought the daVinci™ robot to Tulane University Hospital in November 2002 (the first center in the entire Gulf South to provide this cutting edge technology), primarily for management of prostate cancer.
Recent News in Prostate Cancer
Genetic mutation shown in some men with prostate cancer
[Meredith Cohn]
"Researchers at Johns Hopkins and the University of Michigan have discovered an inherited mutation linked to significantly higher risk of prostate cancer development at a younger age."
Tulane Urology listed among best hospitals
"Hospitals that made the list can provide first rate care. The city-by-city lists include hospitals that are among the nation's best in handling difficult cases in a list of medical specialties. Tulane was singled out for its work with kidneys. Tulane received high-performance marks in cancer, geriatrics, orthopedics, and urology."
[from Times-Picayune]
Treatment tested at Tulane Urology helps those with
recurring prostate cancer
Prostate cancer is the second most common cause of cancer death in men, taking the lives of 30,000 men in the U.S. each year, according to the American Cancer Society. Caught early, before it spreads, it is very curable.
Dr. Benjamin Lee is the principal investigator at Tulane for brand new technology being tested in New Orleans and at 14 other sites in the country. It's for men whose prostate cancer has come back and who had external beam radiation the first time around.
Latest Research from Tulane UrologyNew York Times features promising study co-led by Oliver Sartor of Tulane Cancer Center and Tulane Urology
"A new drug being developed by Sanofi-Aventis extended the lives of men with advanced prostate cancer in a clinical trial and could become a new last-ditch treatment, researchers reported Wednesday..." (CLICK HERE TO READ MORE)
Also featured locally in the Times Picayune:
"An international study led by a Tulane University cancer specialist found that a new prostate-cancer drug increases survival by 30 percent in men with advanced stages of this strain..."
(READ MORE on nola.com)
Link to Tulane's New Wave article
New Clinical Trial Opened at Tulane Medical Center - Treatment of Locally Recurrent Prostate Cancer with HIFU (High Intensity Focused Ultrasound)
High Intensity Focused Ultrasound, or HIFU, is a therapy that destroys tissue with rapid heat elevation-which essentially destroys the tissue. Ultrasound energy, or sound waves, is focused at a specific location and at that “focal point,” the temperature raises to almost 90 degrees Celsius in a matter of seconds. Any tissue at the “focal point” is destroyed; however, any tissue outside of the focal point remains unharmed.
(CLICK HERE TO READ MORE)
